Advertisement
Advertisement

ARWR

ARWR logo

Arrowhead Research Corporation

85.11
USD
Sponsored
-1.23
-1.42%
Sep 08, 15:59 UTC -4
Closed
exchange

After-Market

85.96

+0.85
+1.00%

Arrowhead Research Corporation Profile

About

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Info & Links

CEO

Christopher Anzalone

Headquarters

177 E. Colorado Blvd, Suite 700
Pasadena, CA 91105, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.arrowheadpharma.com

Auditor

KPMG LLP

Share holders

86

Employees

711

Arrowhead Research Corporation Statistics

Valuation Measures

Market Capitalization2

12.14B

Enterprise Value

12.95B

Enterprise Value/EBITDA(ttm)

-63.31

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

18.17

Price to Book(mrq)

26.10

Price to Cash(ytd)

723.11

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-47.79%

Profit Margin(ttm)

-108.94%

Return on Equity(ttm)

-60.06%

Return on Invested Capital(ttm)

-17.28%

Return on Assets(ttm)

-17.37%

Income Statement

Revenue(ttm)

669.50M

Revenue Per Share(ttm)

4.74

Gross Profit(ttm)

669.50M

EBITDA(ttm)3

-204.58M

Net Income Available to Common(ttm)

-319.95M

Diluted EPS(ttm)

-2.25

Share Statistics

Beta (5Y Monthly)

1.28

52-Week Change

192.73%

S&P 500 52-Week Change

18.98%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

141.25M

Dividend Yield

0.00%

Float4

135.79M

% Held by Insiders

3.60%

% Held by Institutions

62.61%

Balance Sheet

Total Cash(mrq)

1.60B

Total Cash Per Share(mrq)

11.34

Total Debt(mrq)

864.07M

Total Debt/Equity(mrq)

185.41%

Current Ratio(mrq)

5.90%

Quick Ratio(mrq)

5.90%

Book Value Per Share(mrq)

3.30

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.55

Free Cash Flow(ytd)

-88.11M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement